Advice
Following a full submission
Anastrozole (Arimidex) is accepted for restricted use within NHS Scotland in the adjuvant treatment of postmenopausal women with hormone receptor-positive early invasive breast cancer. Anastrozole has shown benefit over standard anti-oestrogen therapy in terms of disease-free survival in this patient group. It offers an alternative to tamoxifen and has a different adverse effects profile. Treatment with anastrozole should be initiated by a breast cancer specialist.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- Anastrozole 1mg tablets (Arimidex®)
- SMC ID:
- 198/05
- Indication:
- Adjuvant treatment of postmenopausal women with oestrogen receptor- positive early invasive breast cancer
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 September 2005